Tirzepatide for Sleep Apnea: Which Patients See

How Does Tirzepatide Improve Obstructive Sleep Apnea?

Obstructive sleep apnea occurs when the upper airway collapses repeatedly during sleep, and obesity is the single strongest modifiable risk factor. Excess soft tissue around the neck, tongue, and pharyngeal walls narrows the airway, while abdominal fat reduces lung volume and further destabilizes breathing. Tirzepatide, a once-weekly injectable that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, produces substantial and sustained weight loss that targets these anatomical contributors.

The U.S. Food and Drug Administration approved tirzepatide (Zepbound) specifically for moderate-to-severe OSA in adults with obesity in late 2024, based on the SURMOUNT-OSA trials. Those phase 3 studies showed meaningful reductions in the apnea-hypopnea index (AHI) compared with placebo, both in patients using continuous positive airway pressure (CPAP) and in those not on PAP therapy. Eli Lilly and independent researchers are now examining which patient subgroups derive the largest clinical benefit.

Which Patients Benefit Most from Tirzepatide for OSA?

Analyses presented at recent sleep medicine and obesity conferences suggest that response to tirzepatide is not uniform. Patients with higher starting body mass index and more severe baseline OSA generally experience the largest absolute drop in AHI, partly because they have more disease to lose. Distribution of body fat also appears to matter: individuals with prominent central or upper-body adiposity, including neck circumference, may benefit disproportionately because that tissue most directly compresses the airway.

Clinicians are increasingly considering tirzepatide as an adjunct, not a replacement, for established OSA therapies. Many patients still require CPAP, oral appliances, or positional therapy after weight loss, particularly if their apnea has a strong anatomical or neuromuscular component unrelated to obesity. Shared decision-making, weighing cardiometabolic benefits, gastrointestinal side effects, and cost, remains central to prescribing.